• Je něco špatně v tomto záznamu ?

Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL

M. Kotrova, VHJ. van der Velden, JJM. van Dongen, R. Formankova, P. Sedlacek, M. Brüggemann, J. Zuna, J. Stary, J. Trka, E. Fronkova,

. 2017 ; 52 (7) : 962-968. [pub] 20170227

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010777

Grantová podpora
NV16-32568A MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek

E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 28244980
DOI 10.1038/bmt.2017.16
Knihovny.cz E-zdroje

Minimal residual disease (MRD) monitoring via quantitative PCR (qPCR) detection of Ag receptor gene rearrangements has been the most sensitive method for predicting prognosis and making post-transplant treatment decisions for patients with ALL. Despite the broad clinical usefulness and standardization of this method, we and others have repeatedly reported the possibility of false-positive MRD results caused by massive B-lymphocyte regeneration after stem cell transplantation (SCT). Next-generation sequencing (NGS) enables precise and sensitive detection of multiple Ag receptor rearrangements, thus providing a more specific readout compared to qPCR. We investigated two cohorts of children with ALL who underwent SCT (30 patients and 228 samples). The first cohort consisted of 17 patients who remained in long-term CR after SCT despite having low MRD positivity (<0.01%) at least once during post-SCT monitoring using qPCR. Only one of 27 qPCR-positive samples was confirmed to be positive by NGS. Conversely, 10 of 15 samples with low qPCR-detected MRD positivity from 13 patients who subsequently relapsed were also confirmed to be positive by NGS (P=0.002). These data show that NGS has a better specificity in post-SCT ALL management and indicate that treatment interventions aimed at reverting impending relapse should not be based on qPCR only.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010777
003      
CZ-PrNML
005      
20180404142257.0
007      
ta
008      
180404s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/bmt.2017.16 $2 doi
035    __
$a (PubMed)28244980
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kotrova, M $u CLIP Laboratory Centre, Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
245    10
$a Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL / $c M. Kotrova, VHJ. van der Velden, JJM. van Dongen, R. Formankova, P. Sedlacek, M. Brüggemann, J. Zuna, J. Stary, J. Trka, E. Fronkova,
520    9_
$a Minimal residual disease (MRD) monitoring via quantitative PCR (qPCR) detection of Ag receptor gene rearrangements has been the most sensitive method for predicting prognosis and making post-transplant treatment decisions for patients with ALL. Despite the broad clinical usefulness and standardization of this method, we and others have repeatedly reported the possibility of false-positive MRD results caused by massive B-lymphocyte regeneration after stem cell transplantation (SCT). Next-generation sequencing (NGS) enables precise and sensitive detection of multiple Ag receptor rearrangements, thus providing a more specific readout compared to qPCR. We investigated two cohorts of children with ALL who underwent SCT (30 patients and 228 samples). The first cohort consisted of 17 patients who remained in long-term CR after SCT despite having low MRD positivity (<0.01%) at least once during post-SCT monitoring using qPCR. Only one of 27 qPCR-positive samples was confirmed to be positive by NGS. Conversely, 10 of 15 samples with low qPCR-detected MRD positivity from 13 patients who subsequently relapsed were also confirmed to be positive by NGS (P=0.002). These data show that NGS has a better specificity in post-SCT ALL management and indicate that treatment interventions aimed at reverting impending relapse should not be based on qPCR only.
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a falešně pozitivní reakce $7 D005189
650    _2
$a ženské pohlaví $7 D005260
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    12
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a reziduální nádor $7 D018365
650    12
$a polymerázová řetězová reakce $7 D016133
650    12
$a akutní lymfatická leukemie $x krev $x diagnóza $x genetika $x terapie $7 D054198
650    _2
$a prognóza $7 D011379
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a van der Velden, V H J $u Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
700    1_
$a van Dongen, J J M $u Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
700    1_
$a Formankova, R $u Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Sedlacek, P $u Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Brüggemann, M $u Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany.
700    1_
$a Zuna, J $u CLIP Laboratory Centre, Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Stary, J $u Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Trka, J $u CLIP Laboratory Centre, Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Fronkova, E $u CLIP Laboratory Centre, Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 52, č. 7 (2017), s. 962-968
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28244980 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404142337 $b ABA008
999    __
$a ok $b bmc $g 1288262 $s 1007589
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 52 $c 7 $d 962-968 $e 20170227 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
GRA    __
$a NV16-32568A $p MZ0
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace